Results 121 to 130 of about 1,201,269 (362)

Are Thousands of Samples Really Needed to Generate Robust Gene-List for Prediction of Cancer Outcome? [PDF]

arXiv, 2016
The prediction of cancer prognosis and metastatic potential immediately after the initial diagnoses is a major challenge in current clinical research. The relevance of such a signature is clear, as it will free many patients from the agony and toxic side-effects associated with the adjuvant chemotherapy automatically and sometimes carelessly subscribed
arxiv  

Optimal chemotherapy and immunotherapy schedules for a cancer-obesity model with Caputo time fractional derivative [PDF]

, 2018
This work presents a new mathematical model to depict the effect of obesity on cancerous tumor growth when chemotherapy as well as immunotherapy have been administered. We consider an optimal control problem to destroy the tumor population and minimize the drug dose over a finite time interval.
arxiv   +1 more source

Electrical Stimulation Therapy – Dedicated to the Perfect Plastic Repair

Advanced Science, EarlyView.
This review discusses various types of electrical stimulation sources and materials, delving into the roles and mechanisms of electrical stimulation therapy in plastic surgery for tissue repair. This work broadens the clinical perspective of electrical stimulation, covering diverse repair needs from bone to soft tissues, and provides insights into ...
Kexin Deng, Ruizeng Luo, Ying Chen, Xiaoqiang Liu, Yuanyin Xi, Muhammad Usman, Xupin Jiang, Zhou Li, Jiaping Zhang   +8 more
wiley   +1 more source

Nonlinear cancer chemotherapy: modelling the Norton-Simon hypothesis [PDF]

, 2018
A fundamental model of tumor growth in the presence of cytotoxic chemotherapeutic agents is formulated. The model allows to study the role of the Norton-Simon hypothesis in the context of dose-dense chemotherapy. Dose-dense protocols aim at reducing the period between courses of chemotherapy from three weeks to two weeks, in order to avoid tumor ...
arxiv   +1 more source

PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer

Annals of Oncology, 2017
Background The expression of programmed death (PD) ligand 1 (PD-L1) protein expression assessed by immunohistochemistry (IHC) has been correlated with response and survival benefit from anti-PD-1/PD-L1 immune checkpoint inhibitor therapies in advanced ...
Ming S Tsao, G. L. Teuff, Frances A. Shepherd, Camille Landais, Pierre Hainaut, M. Filipits, Robert Pirker, T. L. Chevalier, S. Graziano, R. Kratze, J. Soria, J. Pignon, Lesley Seymour, Elisabeth Brambilla   +13 more
semanticscholar   +1 more source

Antigen‐Targeting Inserted Nanomicelles Guide Pre‐Existing Immunity to Kill Head and Neck Cancer

Advanced Science, EarlyView.
This study introduces a tumor‐targeted nanomicelle platform (preS1‐pHLIP) that exploits pre‐existing antiviral immunity to combat heterogeneous cancers. By delivering viral antigens to label tumors as virus‐like targets, the nanomicelles activate antiviral B and T cells, triggering in situ tumor lysis.
Lizhuo Zhang, Qingqing Feng, Chuanming Zheng, Yuanqiang Li, Xinyang Ge, Tiefeng Jin, Gaofeng Hu, Zhuo Tan, Jiafeng Wang, Jiajie Xu, Liehao Jiang, Dan Wang, Zhangguo Ying, Xiao Zhao, Keman Cheng, Qinglin Li, Minghua Ge   +16 more
wiley   +1 more source

Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)

BMC Cancer, 2018
At time of diagnosis, less than 10% of patients with pancreatic adenocarcinomas (PDAC) are considered to be immediately operable (i.e. resectable). Considering their poor overall survival (OS), only tumours without vascular invasion (NCCN 2017) should be
L. Schwarz, D. Vernerey, J. Bachet, J. Tuech, F. Portales, P. Michel, A. S. Cunha   +6 more
semanticscholar   +1 more source

Adjuvant Chemotherapy for Endometrial Cancer

International Journal of Gynecological Cancer, 2010
High-risk endometrial cancer (EC), only 15% of all EC, mainly affects elderly women, often with significant comorbid diseases. Because patients with high-risk EC are at increased risk of distant metastases and EC death, the use of adjuvant chemotherapy has been investigated in several trials.
openaire   +7 more sources

Targeting Replication Fork Processing Synergizes with PARP Inhibition to Potentiate Lethality in Homologous Recombination Proficient Ovarian Cancers

Advanced Science, EarlyView.
This study demonstrates that the resveratrol analogue, trans‐4,4′‐dihydroxystilbene (DHS), exhibits synergistic anti‐tumor activity with the PARP inhibitor talazoparib, inducing significant ovarian cancer cell death. The synergistic effect of this combination arises from the concurrent downregulation of homologous recombination factors and the ...
Ganesh Pai Bellare, Kshama Kundu, Papiya Dey, Krupa Thankam Philip, Nitish Chauhan, Muskan Sharma, Sankarsingh Kesharsingh Rajput, Birija Sankar Patro   +7 more
wiley   +1 more source

Update on Adjuvant Chemotherapy for Early Breast Cancer

Breast Cancer: Basic and Clinical Research, 2014
Breast cancer is the second most common cancer in women worldwide. Although most women are diagnosed with early breast cancer, a substantial number recur due to persistent micro-metastatic disease. Systemic adjuvant chemotherapy improves outcomes and has
Murtuza M. Rampurwala, Gabrielle B. Rocque, Mark E. Burkard   +2 more
doaj   +1 more source